Cellenkos Receives FDA Clearance for CK0801 Phase 2 Trial in Aplastic Anemia

Key Takeaways

• FDA cleared Cellenkos to begin Phase 2 multicenter trial of CK0801 for aplastic anemia treatment
• CK0801 uses allogeneic cord blood-derived regulatory T cells (Tregs) to potentially reduce transfusion dependence
• Trial NCT07499102 will evaluate safety and efficacy in transfusion-dependent aplastic anemia patients

---

Cellenkos, Inc. announced on April 27, 2026, that the U.S. Food and Drug Administration has granted clearance to initiate a Phase 2 clinical trial of CK0801 for treating aplastic anemia. The Houston-based clinical-stage biotechnology company specializes in developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies.

About the Phase 2 Trial

The multicenter, open-label study (NCT07499102) will evaluate both safety and clinical efficacy of CK0801 in patients with transfusion-dependent aplastic anemia. This rare blood disorder occurs when the bone marrow fails to produce sufficient blood cells, leaving patients dependent on regular blood transfusions.

CK0801 Mechanism of Action

CK0801 represents an innovative approach using allogeneic cord blood-derived regulatory T cells. These specialized immune cells are designed to modulate the immune system’s response, potentially allowing the bone marrow to recover its normal blood cell production function.

Market Impact and Patient Implications

Aplastic anemia affects approximately 2-6 people per million annually in Western countries, representing a significant unmet medical need. Current treatment options include immunosuppressive therapy and bone marrow transplantation, both carrying substantial risks and limitations.

The FDA clearance marks a significant milestone for Cellenkos, validating their Treg-based therapeutic platform. If successful, CK0801 could offer a less invasive alternative to bone marrow transplantation while potentially reducing patients’ dependence on blood transfusions.

What’s Next

The Phase 2 trial will begin enrolling patients with transfusion-dependent aplastic anemia across multiple clinical sites. Primary endpoints will focus on safety parameters and clinical efficacy measures, including potential reduction in transfusion requirements and improvement in blood cell counts.

This regulatory milestone positions Cellenkos to advance their lead asset toward potential commercialization, pending successful trial outcomes and future regulatory approvals.

---

Frequently Asked Questions

What does this FDA clearance mean for aplastic anemia patients?

The clearance allows Cellenkos to test CK0801 in Phase 2 trials, potentially offering patients a new treatment option that could reduce their dependence on blood transfusions and provide an alternative to bone marrow transplantation.

When will CK0801 be available to patients?

CK0801 is still in clinical trials. If Phase 2 results are positive, the company would need to complete Phase 3 trials and receive full FDA approval, which typically takes several years.

How does CK0801 differ from current aplastic anemia treatments?

Unlike immunosuppressive drugs or bone marrow transplants, CK0801 uses regulatory T cells from cord blood to potentially restore the bone marrow’s natural function, offering a potentially less invasive approach with fewer side effects.